Letter to the Editor: Long Term Use of Proton Pump Inhibitors and Risk of Stomach Cancer: Population Based Case-Control Study in Five Nordic Countries

Why It Matters

If PPI safety is overstated, clinicians may overlook cancer risk in vulnerable patients, affecting prescribing guidelines and public health policy.

Key Takeaways

• Study grouped all long-term PPI users, ignoring continuous vs intermittent use
• No dose‑response or duration analyses were performed, masking potential risks
• Nordic cohort lacked H. pylori‑eradicated patients, limiting relevance to high‑risk regions
• Indication‑specific risk not examined, conflating reflux and atrophic gastritis patients
• Future studies should use precise exposure metrics and focus on high‑risk subgroups

Pulse Analysis

Proton pump inhibitors are among the most prescribed medications worldwide, valued for their ability to suppress gastric acid and treat conditions ranging from reflux disease to peptic ulcers. Their ubiquity has sparked ongoing debate about long‑term safety, especially after observational studies hinted at a possible association with gastric cancer. The recent BMJ case‑control analysis, encompassing five Nordic nations, concluded that prolonged PPI exposure did not increase the incidence of non‑cardia gastric adenocarcinoma, offering reassurance to clinicians and patients alike.

However, methodological nuances can dramatically alter epidemiologic findings. Dr. Kang’s letter underscores that the study’s binary definition of "long‑term" PPI use—based solely on cumulative defined daily doses—fails to differentiate continuous high‑intensity therapy from intermittent or low‑dose regimens, a distinction crucial for assessing hypergastrinemia‑driven carcinogenesis. Moreover, the absence of dose‑response and duration stratifications obscures potential gradients of risk. The Nordic cohort’s low prevalence of Helicobacter pylori eradication and minimal premalignant gastric lesions further limits the applicability of results to regions where such risk factors are common. Without indication‑specific analyses, the safety signal may not hold for patients with chronic atrophic gastritis or post‑eradication mucosal changes.

For healthcare providers, regulators, and payers, these gaps signal the need for targeted research rather than blanket safety declarations. Future investigations should employ precise exposure metrics, evaluate dose‑ and duration‑response curves, and prioritize high‑risk subpopulations—particularly those with prior H. pylori infection, intestinal metaplasia, or other premalignant conditions. Such data will enable nuanced risk‑benefit assessments, guide prescribing practices, and inform potential label updates, ensuring that the therapeutic advantages of PPIs are balanced against any long‑term oncologic hazards.